Cordis eyes vascular closure market with US trial for ExoSeal device:
This article was originally published in Clinica
As part of efforts to enter the vascular closure device market, Cordis has begun a pivotal US trial of its ExoSeal product for closing punctures in patients undergoing catheterisation procedures. The trial, called ECLIPSE, will assess the safety and efficacy of ExoSeal versus manual compression, as a means of closing vascular access sites in patients who have undergone diagnostic or interventional procedures. It is a non-blinded, randomised study that will encompass 400 patients from 18 medical centres. ExoSeal features a synthetic bioabsorbable polymer and is being studied to determine whether it can enable expedited the cessation of bleeding, faster patient ambulation and reduced bed-stay. Nearly eight million patients undergo cardiac catheterisation procedures annually, said Cordis, a Johnson & Johnson company.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.